Vabysmo

Roche’s Vabysmo reports positive outcomes in multiple eye diseases
Roche’s Vabysmo reports positive outcomes in multiple eye diseases
Clinical Trials Arena
Roche
Vabysmo
diabetic macular edema
wet age-related macular degeneration
Flag link:
FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
BioSpace
Roche
Genentech
FDA
Vabysmo
macular edema
retinal vein occlusion
Flag link:
Roche’s new eye drug pressures Eylea with strong launch
Roche’s new eye drug pressures Eylea with strong launch
BioPharma Dive
Roche
Vabysmo
Eylea
earnings
Regeneron
Flag link:
Genentech opens up eye patients’ world with Vabysmo
Genentech opens up eye patients’ world with Vabysmo
Medical Marketing and Media
Genentech
Vabysmo
wet age-related macular degeneration
DTC ads
Flag link:
Trials cue up new use for Roche's eye disease drug Vabysmo
Trials cue up new use for Roche's eye disease drug Vabysmo
Pharmaphorum
Roche
Vabysmo
clinical trials
retinal vein occlusion
Flag link:
A year of two halves for US approvals
A year of two halves for US approvals
EP Vantage
FDA
drug approvals
Mounjaro
Eli Lilly
Vabysmo
Roche
Opdualag
Bristol Myers Squibb
Carvykti
JNJ
Vtama
Roivant
Pluvicto
Novartis
Flag link:
Roche's Vabysmo lands clinical counterpunch in ophthalmology brawl with Eylea
Roche's Vabysmo lands clinical counterpunch in ophthalmology brawl with Eylea
Fierce Pharma
Roche
Genentech
Vabysmo
bispecific antibodies
Eylea
Flag link:
Look out, Regeneron. As the threat from Roche's Vabysmo grows, one team of analysts slashes its Eylea sales estimate
Look out, Regeneron. As the threat from Roche's Vabysmo grows, one team of analysts slashes its Eylea sales estimate
Fierce Pharma
Regeneron
Eylea
Roche
Vabysmo
Flag link:
Regeneron's Eylea could lose 30% of its patients to Roche's Vabysmo over the next year: analyst survey
Regeneron's Eylea could lose 30% of its patients to Roche's Vabysmo over the next year: analyst survey
Fierce Pharma
Regeneron
Eylea
Vabysmo
Roche
wet-AMD
Flag link:
The biggest launches of 2022: a reboot
The biggest launches of 2022: a reboot
EP Vantage
drug launches
Eli Lilly
tirzepatide
Alnylam
vutrisiran
Roche
Vabysmo
JNJ
Carvykti
Mirati Therapeutics
adagrasib
Bristol Myers Squibb
mavacamten
deucravacitinib
Flag link:
Roche pharma CEO Anderson talks up Vabysmo’s 'very strong launch' plans as Eylea battle looms
Roche pharma CEO Anderson talks up Vabysmo’s 'very strong launch' plans as Eylea battle looms
Fierce Pharma
Roche
Vabysmo
drug launches
Bill Anderson
Eylea
Flag link:
Roche looks to compete against a blockbuster with its newly approved vision drug
Roche looks to compete against a blockbuster with its newly approved vision drug
Stat
Roche
FDA
bispecific antibodies
Regeneron
Vabysmo
wet age-related macular degeneration
diabetic macular edema
Flag link: